7-Chloro-1-ethyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid

We are 7-Chloro-1-ethyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid CAS:68077-26-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   7-Chloro-1-ethyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
CAS.NO: 68077-26-9
Synonyms:
7-chloro-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid

Molecular Formula:C12H9ClFNO3
Molecular Weight: 269.65600

Physical and Chemical Properties:
Density: 1.489 g / cm3
Boiling point: 437.9ºC at 760 mmHg
Melting point: 245 ° C
Flash point: 218.7ºC
Refractive index: 1.601

Specification:
Appearance:white powder
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:
Intermediates of Norfloxacin CAS: 70458-96-7

Related News: Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease.56341-41-4 At the same time, through years of imitation and advanced technology learning, more and more domestic companies have participated in the field of highly original and characteristic APIs.N,N'-bis(4-bromophenyl)-N,N'-bis(4-methylphenyl)-[1,1'-Biphenyl]-4,4'-diamine The glucagon-only configuration may be helpful in rare conditions that often lead to chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI).2,2-dietoxiacetofenona CAS:6175-45-7 The glucagon-only configuration may be helpful in rare conditions that often lead to chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI).The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).